Pasithea Therapeutics Corp (NASDAQ:KTTA) (NASDAQ:KTTA) CEO Tiago Reis Marques talks to Proactive about the newly Nasdaq-listed Miami, Florida-based biotechnology company 's focus on psychiatric and neurological disorders with its at-home clinics.
Marques says while its biotech operations will focus on developing drugs that target mental health disorders at the same time it is establishing in-home, mobile, anti-depression clinics in the UK and in New York and California within the US, with the plan to expand nation-wide. The group will initially focus its services on administering in-home ketamine infusions to help its patients.